---
layout: post
title: "Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight"
date: 2026-02-18T11:45:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-delivered-superior-efficacy-in-first-of-its-kind-phase-3b-trial-for-adults-with-psoriasis-and-obesity-or-overweight-302691124.html
significance: 7.00
---

<p>At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and â‰¥10% weight loss In a key secondary endpoint, patients taking Taltz and Zepbound were 40% more likely to...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-delivered-superior-efficacy-in-first-of-its-kind-phase-3b-trial-for-adults-with-psoriasis-and-obesity-or-overweight-302691124.html)

**Published:** 2026-02-18 11:45:00 +0000

**Significance Score:** 7.00

[View original](https://www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-delivered-superior-efficacy-in-first-of-its-kind-phase-3b-trial-for-adults-with-psoriasis-and-obesity-or-overweight-302691124.html)
